HUS and TTP in children

Pediatric Clinics of North America

Volumn 60, Issue 6, 2013, Pages 1513-1526

  Trachtman, Howard ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alternative pathway of complement (APC); Hemolytic uremic syndrome (HUS); Shiga toxin (Stx); Thrombotic microangiopathy (TMA); Thrombotic thrombocytopenic purpura (TTP)

Indexed keywords

ECULIZUMAB; SHIGA TOXIN;

AGE DISTRIBUTION; BACTERIAL STRAIN; CELL DAMAGE; CHILD; CLINICAL FEATURE; COMPLEMENT ALTERNATIVE PATHWAY; DISEASE CLASSIFICATION; ENDOTHELIUM CELL; ESCHERICHIA COLI INFECTION; FAMILIAL DISEASE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY INJURY; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ALTERNATIVE PATHWAY OF COMPLEMENT (APC); HEMOLYTIC UREMIC SYNDROME (HUS); SHIGA TOXIN (STX); THROMBOTIC MICROANGIOPATHY (TMA); THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP);

CHILD; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84887550319     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2013.08.007     Document Type: Review

References (54)

1. Moake J.L. Moschcowitz, multimers, and metalloprotease. NEngl J Med 1998, 339:1629-1631.
2. Karmali M.A., Petric M., Lim C., et al. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. JInfect Dis 1985, 151:775-782.
3. Moake J.L., Rudy C.K., Troll J.H., et al. von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura. Am J Med Sci 1986, 291:47-50.
4. Moake J.L., Turner N.A., Stathopoulos N.A., et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. JClin Invest 1986, 78:1456-1461.
5. Warwicker P., Goodship T.H., Donne R.L., et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998, 53:836-844.
6. Kavanagh D., Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431-2442.
7. Noris M., Mescia F., Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012, 8:622-633.
8. Chapman K., Seldon M., Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost 2012, 38:47-54.
9. Copelovitch L., Kaplan B.S. The thrombotic microangiopathies. Pediatr Nephrol 2008, 23:1761-1767.
10. Tarr P.I., Gordon C.A., Chandler W.L. Shiga-toxin-producing Escherichia coli and hemolytic uremic syndrome. Lancet 2005, 365:1073-1086.
11. Philpott D.J., Ackerley C.A., Kiliaan A.J., et al. Translocation of verotoxin-1 across T84 monolayers: mechanism of bacterial toxin penetration of epithelium. Am J Physiol 1997, 273(6 Pt 1):G1349-G1358.
12. Brigotti M., Tazzari P.L., Ravanelli E., et al. Clinical relevance of shiga toxin concentrations in the blood of patients with hemolytic uremic syndrome. Pediatr Infect Dis J 2011, 30:486-490.
13. Sandvig K., Bergan J., Dyve A.B., et al. Endocytosis and retrograde transport of Shiga toxin. Toxicon 2010, 56:1181-1185.
14. Mukhopadhyay S., Linstedt A.D. Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis. Science 2012, 335:332-335.
15. Petruzziello-Pellegrini T.N., Marsden P.A. Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens 2012, 21:433-440.
16. King L.A., Nogareda F., Weill F.X., et al. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, 2011. Clin Infect Dis 2012, 54:1588-1594.
17. Petruzziello-Pellegrini T.N., Yuen D.A., Page A.V., et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. JClin Invest 2012, 122:759-776.
18. Thurman J.M., Marians R., Emlen W., et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009, 4:1920-1924.
19. Java A., Atkinson J., Salmon J. Defective complement inhibitory function predisposes to renal disease. Annu Rev Med 2013, 64:307-324.
20. De Ceunynck K., De Meyer S.F., Vanhoorelbeke K. Unwinding the von Willebrand factor strings puzzle. Blood 2013, 121:270-277.
21. Clark W.F. Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial 2012, 25:214-219.
22. Lotta L.A., Wu H.M., Cairo A., et al. Drop of residual plasmatic activity of ADAMTS13 to undetectable levels during acute disease in a patient with adult-onset congenital thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2013, 50:59-60.
23. Constantinescu A.R., Bitzan M., Weiss L.S., et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004, 43:976-982.
24. Final report and analysis of the epidemiology of the 2011 O104:H4 EHEC-HUS outbreak in Germany 2011, Robert Koch Institut, Berlin.
25. Tarr P.I., Karpman D. Escherichia coli O104:H4 and the hemolytic uremic syndrome: the analysis begins. Clin Infect Dis 2012, 55:760-763.
26. Hedican E.B., Medus C., Besser J.M., et al. Characteristics of O157 versus non-O157 Shiga toxin-producing Escherichia coli infections in Minnesota, 2000-2006. Clin Infect Dis 2009, 49:358-364.
27. Banerjee R., Hersh A.L., Newland J., Emerging Infections Network Hemolytic-Uremic Syndrome Study Group, et al. Streptococcus pneumoniae-associated hemolytic uremic syndrome among children in North America. Pediatr Infect Dis J 2011, 30:736-739.
28. Taylor C.M., Machin S., Wigmore S.J., Working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplantation Society, et al. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010, 148:37-47.
29. Eremina V., Jefferson J.A., Kowalewska J., et al. VEGF inhibition and renal thrombotic microangiopathy. NEngl J Med 2008, 358:1129-1136.
30. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12:642-649.
31. Bresin E., Rurali E., Caprioli J., European Working Party on Complement Genetics in Renal Diseases, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. JAm Soc Nephrol 2013, 24:475-486.
32. Fremeaux-Bacchi V., Fakhouri F., Garnier A., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554-562.
33. Lemaire M., Frémeaux-Bacchi V., Schaefer F., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45(5):531-536. 10.1038/ng.2590.
34. Wu L.H., Yu F., Qu Z., et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int 2013, 83:715-723.
35. Yoshioka K., Yagi K., Moriguchi N. Clinical features and treatment of children with hemolytic uremic syndrome caused by enterohemorrhagic Escherichia coli O157:H7 infection: experience of an outbreak in Sakai City, 1996. Pediatr Int 1999, 41:223-227.
36. Hoefer D., Hurd S., Medus C., Emerging Infections Program FoodNet Working Group, et al. Laboratory practices for the identification of Shiga toxin-producing Escherichia coli in the United States, FoodNet sites, 2007. Foodborne Pathog Dis 2011, 8:555-560.
37. Lotta L.A., Wu H.M., Musallam K.M., et al. The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood Rev 2013, 27:71-76.
38. Trachtman H., Austin C., Lewinski M., et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 2012, 8:658-669.
39. Trachtman H., Cnaan A., Christen E., et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003, 290:1337-1344.
40. Ake J.A., Jelacic S., Ciol M.A., et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005, 115:e673-e680.
41. Hickey C.A., Beattie T.J., Cowieson J., et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011, 165:884-889.
42. Schulman S.L., Kaplan B.S. Management of patients with hemolytic uremic syndrome demonstrating severe azotemia but not anuria. Pediatr Nephrol 1996, 10:671-674.
43. Lapeyraque A.L., Malina M., Fremeaux-Bacchi V., et al. Eculizumab in severe Shiga-toxin-associated HUS. NEngl J Med 2011, 364(26):2561-2563.
44. European Centre for Disease Prevention and Control. Shiga toxin-producing Ecoli (STEC): update on outbreak in the EU. 2011. Available at: Accessed August 9, 2011. http://www.ecdc.europa.eu/en/healthtopics/escherichia_coli/whats_new/Pages/epidemiological_updates.aspx.
45. Loos S., Ahlenstiel T., Kranz B., et al. An outbreak of Shiga-toxin producing E. coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 2012, 55:753-759.
46. Colic E., Dieperink H., Titlestad K., et al. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011, 378:1089-1093.
47. Clark W.F., Sontrop J.M., Macnab J.J., et al. Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study. BMJ 2010, 341:c6020.
48. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic uremic syndrome. NEngl J Med 2013, 368:2169-2181.
49. Lou-Meda R., Oakes R.S., Gilstrap J.N., et al. Prognostic significance of microalbuminuria in postdiarrheal hemolytic uremic syndrome. Pediatr Nephrol 2007, 22:117-120.
50. Westwood J.P., Webster H., McGuckin S., et al. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. JThromb Haemost 2013, 11:481-490.
51. Spinale J.M., Ruebner R.L., Copelovitch L., et al. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013, [Epub ahead of print].
52. Oakes R.S., Siegler R.L., McReynolds M.A., et al. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 2006, 117:1656-1662.
53. Oakes R.S., Kirkham J.K., Nelson R.D., et al. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008, 23:1303-1308.
54. Garg A.X., Suri R.S., Barrowman N., et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003, 290:1360-1370.